New targets and new targeted treatments for metastatic colorectal cancer (BRAF, HER2, KRAS G12C, NTRK, bispecific antibodies, etc.)

The development of new therapies has made it possible to extend the life expectancy of patients with colorectal cancer with metastases. New targeted treatments are currently being developed. Several therapeutic targets have been well identified and some targeted treatments could become the standard treatments of tomorrow. For example, we can cite the importance of a treatment targeting the BRAF V600E mutation, the overexpression of HER2, the fusion of NTRK, or the option of immunotherapy in MSI/dMMR cancers.
Thus in 2025, the management of colorectal cancer justifies knowledge of potential targets and in particular the KRAS, NRAS, BRAF, HER2, and MSI/dMMR status.